Detalles de la búsqueda
1.
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Lancet Oncol
; 13(12): 1260-70, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23151431
2.
Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.
Oncology
; 82(1): 56-8, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22310055
3.
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.
Lancet Oncol
; 9(11): 1058-68, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18929505
4.
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer.
Radiother Oncol
; 105(2): 184-92, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23127770
5.
Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point.
Pathology
; 42(4): 339-43, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20438406
6.
Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
Cancer
; 115(19): 4477-87, 2009 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19691097
7.
Is HFE involved in increased hepcidin expression and hypoferremia in inflammation and anemia of chronic disease?
Hepatology
; 41(4): 936-8, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15791616
Resultados
1 -
7
de 7
1
Próxima >
>>